NCT02333110 GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
| NCT ID | NCT02333110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital |
| Condition | Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2015-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2015-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.
Eligibility Criteria
Inclusion Criteria: * Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible. * Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation * Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis * WHO performance status of 0-2 * Aged 18 years or older * Ability to sign and understand an informed consent form Exclusion Criteria: * Potentially curable patient * Previous palliative radiation with hypofractionation * Tumor located near the spinal cord or in the brain * Pregnant or nursing woman
Contact & Investigator
Te Vuong, MD
PRINCIPAL INVESTIGATOR
Sir Mortimer Jewish General Hospital
Frequently Asked Questions
Who can join the NCT02333110 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02333110 currently recruiting?
Yes, NCT02333110 is actively recruiting participants. Contact the research team at luciana.poggi.trinidad.ccomtl@ssss.gouv.qc.ca for enrollment information.
Where is the NCT02333110 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT02333110 clinical trial?
NCT02333110 is sponsored by Sir Mortimer B. Davis - Jewish General Hospital. The principal investigator is Te Vuong, MD at Sir Mortimer Jewish General Hospital. The trial plans to enroll 50 participants.